Tag: biopharma
Indian pharma industry welcomes FDA move to accelerate biosimilar development
The FDA released a new draft guidance proposing major changes to simplify biosimilarity studies and reduce unnecessary clinical testing
India breaks into top 10 in Cytiva’s 2025 Global Biopharma Index
India climbs five places in global ranking, driven by growing R&D capacity and generics strength
Enzene wins Manufacturing Excellence Award at CPHI Frankfurt
The Enzene platform was one of four finalists selected by a panel of pharma industry experts.
India’s healthcare & pharma deals surge in Q3 2025 driven by...
The surge was driven by seven high value deals worth USD 2.6 billion, reflecting renewed investor confidence in scale and consolidation plays across pharma, biotech, and hospital segments
IGMPI strengthens leadership in specialized training for pharma a allied industries
With a sharp focus on Good Manufacturing Practices (GMP), Quality Assurance, and Regulatory Affairs, the institute equips learners to navigate complex compliance environments and uphold international standards of safety and quality.
Hikal inaugurates HPAPI Lab at its Pune Innovation Centre
The facility has been designed with a range of advanced features to ensure both safety and efficiency
WHO prequalifies Shantha Biotech’s ‘Shanchol’ Oral Cholera Vaccine to ensure global...
This milestone enables global procurement agencies such as UNICEF, Gavi, and PAHO to source Shanchol® for use in countries where cholera remains a major public health challenge
Indian pharma firms set for 7–9% revenue growth in FY26 despite...
ICRA maintains a stable outlook on the pharmaceuticals sector, supported by sustained demand in both domestic and export markets
Premas Biotech wins Gates Foundation grant to advance thermostable rabies vaccine
Funding to support early-stage development of innovative rabies vaccine for low- and middle-income countries
Top 20 global biopharma companies report 5.7% fall in market capitalization...
Tariffs, pricing pressures erode $200 billion in value for top biopharma firms; Alnylam and Novartis buck the trend with strong gains